Newsroom
Cureus August 2022 Newsletter
Hi, In this edition of the Cureus newsletter, we're highlighting some recently published articles from the previous month as well as promotion tips and recent calls for articles. And don't forget to make your Cureus picture prognosis this week! Looking for some light reading? Why not try one of our featured articles? ‘Digital Wellbeing’: The Need of the Hour in Today’s Digitalized and Technology Driven World! by Nisha M. Thomas, Sonali G. Choudhari, Abhay M. Gaidhane, Zahiruddin Quazi Syed Ketamine and Its Emergence in the Field of Neurology by Luis Rueda Carrillo, Klepper Alfredo Garcia, Nilufer Yalcin, Manan Shah Unprovoked Submassive Saddle Pulmonary Embolism in an Adult Male After Pfizer COVID-19 Vaccination by Blaire D. Borisoff, Katherine D. Bohn, Justin Sager, Barbara L. Gracious
Aug 11, 2022
Radiological Determinants of Thromboembolic Events in COVID-19 Pneumonia: A Retrospective Study
Read the full story from healthimaging.com "New research highlights key CT findings that radiologists should be aware of when interpreting the exams of patients with COVID pneumonia. The paper details an analysis of 276 COVID patients and how their image findings correlated to their experiences with thromboembolic events. Corresponding author of the paper Mohd Ghadeeb, MD, from the Radiology Department at King Fahad Hospital in Saudi Arabia, and colleagues explained the importance and challenges involved in understanding COVID patients’ risks of clotting complications recently in Cureus: 'Thromboembolic manifestations have a wide spectrum and vary significantly among different patients. These include venous thromboembolic events, arterial events, and microvascular thrombosis,” the researchers wrote. “The diagnosis of venous thromboembolic events, including deep venous thrombosis and pulmonary embolism, can be challenging due to overlapping clinical and laboratory features.'"
Aug 11, 2022
A-Fib Linked to Worse Hospital Outcomes in Multiple Myeloma
A Cureus article was recently highlighted in HealthDay. In stratified analysis, odds of all-cause mortality, hospital stay of more than five days higher for MM patients not using anticoagulation Overall, 13.1 percent of hospitalized patients with multiple myeloma (MM) have atrial fibrillation, which is associated with worse outcomes, according to a study recently published in Cureus. Inimfon Jackson, M.D., M.P.H., Ph.D., from Einstein Medical Center in Philadelphia, and colleagues conducted a retrospective cohort analysis using data from the National Inpatient Sample from 2016 to 2018 to explore the prevalence of atrial fibrillation among MM patients and the impact of atrial fibrillation on outcomes. The researchers found that 13.1 percent of the 68,267 hospitalizations with a diagnosis of MM reported having atrial fibrillation. Compared with those without atrial fibrillation, MM patients with atrial fibrillation had increased odds of inpatient all-cause mortality (adjusted odds ratio, 1.16)... You can read the full HealthDay article here.
Jul 21, 2022
Cureus July 2022 Newsletter
Hi, We've made some major changes to the Cureus peer review process that you should know about. All articles in peer review now require two completed reviews from peer reviewers invited by Cureus. The only exception: articles featuring a Cureus Laureate author will only require that one of the two completed reviews be from a Cureus-invited reviewer. We've also eliminated the 21 day exemption for articles that have not received a Cureus-invited review. All articles (except those with a Cureus Laureate author) now require two Cureus-invited reviews. Why did we make these changes? To further bolster the quality and thoroughness of Cureus peer review. Detailed analysis of review times indicate that these changes to our review policy will not have a major effect on article publication times.
Jul 18, 2022
Cureus June 2022 Newsletter
Hi, We're back with the June 2022 installment of the Cureus newsletter. Whether you’re here to publish, peer review, or read the latest medical research, we’re glad you’re part of our community. Are you looking for your reviewer certification letter? We’ve recently tweaked the timing of review acknowledgments. Thank you letters are now sent later in the process, when the article has been either published or rejected. Rest assured, your letter will be available for download from your dashboard when the article has been processed one way or the other. Don't forget that Cureus peer review is now supported on smartphone and tablet devices! Simply highlight the text and tap the “Annotate” button to enter your comment. When finished, tap the “Submit Review” button to view the reviewer questionnaire where you will be prompted to answer a few questions regarding the article. Got a question? We've got answers! We get plenty of questions asking what goes on behind the scenes at Cureus and we’ve updated our FAQ page to address those burning questions. Read about our team, policies, and more here.
Jun 17, 2022
A Case of Idiopathic Cold Agglutinin Hemolytic Anemia Successfully Treated With Steroids
Read the full story from coldagglutininnews.com. A 71-year-old woman with primary cold agglutinin disease (CAD) was successfully treated with the glucocorticoid prednisone, a case study reported. Its scientists noted that primary CAD typically does not respond to glucocorticoids, but in particular instances like this case, it can. The study, “A Case of Idiopathic Cold Agglutinin Hemolytic Anemia Successfully Treated With Steroids,” was published in the journal Cureus. In CAD, autoantibodies known as cold agglutinins bind to red blood cells at low temperatures, causing them to clump together and die in a process called hemolysis. While in primary CAD the cause of the disease is unknown, secondary CAD is associated with an underlying illness, such as an infection, another autoimmune disorder, or some types of cancer.
Jun 10, 2022
Cureus May 2022 Newsletter
Hi, With published articles from over 140 countries, Cureus is leading the way as the most inclusive and affordable Open Access medical research journal. We represent a new generation of medical professionals who value efficiency and open dialogue. Cureus understands the need for both big and small science, and that is why we are one of the few journals accepting and publishing case reports. Whether you’re here to publish, peer review, or read the latest medical research, we’re glad you’re part of our community.
May 17, 2022
Submit Your "Autobiographical Case Report"
Submit your "autobiographical case report." *Now accepting submissions indefinitely. Physicians bring a unique perspective to the understanding of any disease and are often poised to provide lifelong outcomes for chronic diseases and/or their treatments. Many doctors are sitting on a treasure trove of medical knowledge learned firsthand through life experience - insights that never get reported in big clinical studies. Countless potential patients and their physicians can benefit from your wisdom. It’s time to tell your story in a Cureus case report! Please add “Autobiographical Case Report” as a keyword in your submission. We understand you may not have images related to your case, but we strongly encourage you to include any images you do have. Take a look at this published example and submit your case report (all specialties accepted) for the opportunity to be featured on a devoted Autobiographical Case Report page!
May 03, 2022
Presentation Documenting Use of IRRAflow System Confirms Potential Improved Outcomes Compared to Traditional Drainage Solutions
Sponsored by IRRAS Presentation of Largest Dataset to Date Documenting Use of IRRAflow System Confirms Potential Improved Outcomes Compared to Traditional Drainage Solutions The neurosurgery team from the Rockefeller Neuroscience Institute at West Virginia University and WVU Medicine Ruby Memorial Hospital (WVUH), led by Dr. Nicholas Brandmeir, presented the clinical outcomes from the first 45 patients they treated with the new breakthrough technology, IRRAflow, a dynamic system that provides a therapeutic approach to treating intracranial bleeding. The data presented confirms the preliminary effectiveness of the IRRAflow system’s automated irrigation by showing a 0% occlusion rate during the entire course of treatment. On the other hand, clinical literature documents that traditional passive drainage solutions have catheter occlusion rates of up to 47%.1 Additionally, IRRAflow’s mechanism of action was also shown to more effectively remove collected blood after intracranial bleeding. The average treatment time with IRRAflow was 6.8 days, and only 13% of patients required the placement of a shunt after IRRAflow treatment. This percentage of shunt dependence with IRRAflow compares favorably to data from the CLEAR-III where 18% of patients required shunt placement after treatment with a passive ventricular drain. Click the image above to view the PDF and learn about how preliminary data confirms that IRRAflow might reduce rates of catheter occlusion, infections, symptomatic and radiographic vasospasm. 1. Fargen KM, Hoh BL, Neal D, O’Connor T, Rivera-Zengotita M, Murad GJ. The burden and risk factors of ventriculostomy occlusion in a high-volume cerebrovascular practice: results of an ongoing prospective database. Journal of Neurosurgery. 2015:1-8.
Mar 29, 2022
Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Using IRRAflow®
An article on drainage, irrigation, and fibrinolytic therapy (DRIFT) for adult intraventricular hemorrhage published in Cureus was picked up by Medical Device News Magazine Read the Cureus article here: Drainage, Irrigation, and Fibrinolytic Therapy (DRIFT) for Adult Intraventricular Hemorrhage Using IRRAflow® Self-Irrigating Catheter Article from Medical Device News Magazine *Thumbnail image from https://irras.com/
Mar 22, 2022
COVID-19 Infection Can Worsen CAD Symptoms, Report Highlights
COVID-19 can worsen symptoms of cold agglutinin disease (CAD), a recent case report highlights. The scientists stressed the need for further research to determine the best ways to care for people with new or worsening CAD that develops in the context of a COVID-19 infection. In this case, treatment with remdesivir and dexamethasone resulted in “significant improvement in the patient’s condition,” they wrote. Read the full article from Cold Agglutinin Disease News here.
Mar 14, 2022
Breast Cancer Awareness Submissions
We’d like to thank all of the authors who participated in our “Breast Cancer Awareness” call for submissions in honor of Breast Cancer Awareness Month. Breast cancer affects a multitude of specialties and millions of people all over the world and your work continues to power advancements in the fight against this deadly disease Click below to view the articles published on this topic, and stay on the lookout for new calls for article submissions on major clinical topics.
Feb 08, 2022